Sierra Oncology, Inc. (SRRA)
Price:
54.99 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Genmab A/S
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
NEWS
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
zacks.com
2022-06-02 10:33:08GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
businesswire.com
2022-05-05 14:59:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
businesswire.com
2022-05-02 16:57:00CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or vi
Best Biotech Stocks To Buy Now? 5 To Know
stockmarket.com
2022-04-14 13:50:44Check out these biotech stocks with exciting developments today.
SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
prnewswire.com
2022-04-13 15:15:00NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sierra Oncology, Inc. ("Sierra" or the "Company") (NASDAQ: SRRA), in connection with the proposed acquisition of the Company by GlaxoSmithKline plc (NYSE: GSK). Under the terms of the merger agreement, the Company's shareholders will receive $55.00 in cash for each share of Sierra common stock owned.
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
invezz.com
2022-04-13 13:49:54Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA's Momelotinib, a differentiated mode of action with inhibitory activity and critical signalling pathways.
Why Is Sierra Oncology (SRRA) Stock Up Today?
investorplace.com
2022-04-13 11:42:38Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.
Sierra Oncology Stock Is Soaring: Here's Why
benzinga.com
2022-04-13 11:20:09Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an approximate total equity value of $1.9 billion. GSK believes Sierra.
Sierra Oncology Stock Soars After Buyout
schaeffersresearch.com
2022-04-13 10:10:28Sierra Oncology Inc (NASDAQ:SRRA) stock is soaring today, up 38% at $54.52, after news that GlaxoSmithKline (GSK) is purchasing the company for $1.9 billion.
GSK to buy Sierra Oncology for $1.9 billion
marketwatch.com
2022-04-13 08:32:24Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is developing treatments for rare types of cancer, including myelofibrosis, and announced in January that momelotinib met the primary and secondary endpoints in a Phase 3 clinical trial evaluating the experimental therapy as a treatment for myelofibrosis.
Sierra Oncology Soars After Takeover by Glaxo
barrons.com
2022-04-13 08:19:00The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.
Why Sierra Oncology Stock Is Soaring Today
fool.com
2022-04-13 08:14:41GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
benzinga.com
2022-04-13 08:08:02GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab.
Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion
pulse2.com
2022-04-13 08:06:02GlaxoSmithKline plc (NYSE: GSK) announced it is buying Sierra Oncology, Inc (Nasdaq: SRRA) for $1.9 billion (£1.5 billion). These are the details.
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
marketwatch.com
2022-04-13 02:36:00Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.
GSK to buy Sierra Oncology for $1.9 billion
reuters.com
2022-04-13 02:23:00Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday.
No data to display
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
zacks.com
2022-06-02 10:33:08GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
businesswire.com
2022-05-05 14:59:00NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
businesswire.com
2022-05-02 16:57:00CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only $55.00 in cash for each share of Sierra that they own. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (dk@kclasslaw.com), or vi
Best Biotech Stocks To Buy Now? 5 To Know
stockmarket.com
2022-04-14 13:50:44Check out these biotech stocks with exciting developments today.
SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
prnewswire.com
2022-04-13 15:15:00NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sierra Oncology, Inc. ("Sierra" or the "Company") (NASDAQ: SRRA), in connection with the proposed acquisition of the Company by GlaxoSmithKline plc (NYSE: GSK). Under the terms of the merger agreement, the Company's shareholders will receive $55.00 in cash for each share of Sierra common stock owned.
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
invezz.com
2022-04-13 13:49:54Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA's Momelotinib, a differentiated mode of action with inhibitory activity and critical signalling pathways.
Why Is Sierra Oncology (SRRA) Stock Up Today?
investorplace.com
2022-04-13 11:42:38Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.
Sierra Oncology Stock Is Soaring: Here's Why
benzinga.com
2022-04-13 11:20:09Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an approximate total equity value of $1.9 billion. GSK believes Sierra.
Sierra Oncology Stock Soars After Buyout
schaeffersresearch.com
2022-04-13 10:10:28Sierra Oncology Inc (NASDAQ:SRRA) stock is soaring today, up 38% at $54.52, after news that GlaxoSmithKline (GSK) is purchasing the company for $1.9 billion.
GSK to buy Sierra Oncology for $1.9 billion
marketwatch.com
2022-04-13 08:32:24Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is developing treatments for rare types of cancer, including myelofibrosis, and announced in January that momelotinib met the primary and secondary endpoints in a Phase 3 clinical trial evaluating the experimental therapy as a treatment for myelofibrosis.
Sierra Oncology Soars After Takeover by Glaxo
barrons.com
2022-04-13 08:19:00The deal comes ahead of GlaxoSmithKline's planned spinoff of its consumer health division in July.
Why Sierra Oncology Stock Is Soaring Today
fool.com
2022-04-13 08:14:41GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
benzinga.com
2022-04-13 08:08:02GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra's momelotinib complements GSK's Blenrep (belantamab.
Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion
pulse2.com
2022-04-13 08:06:02GlaxoSmithKline plc (NYSE: GSK) announced it is buying Sierra Oncology, Inc (Nasdaq: SRRA) for $1.9 billion (£1.5 billion). These are the details.
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
marketwatch.com
2022-04-13 02:36:00Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.
GSK to buy Sierra Oncology for $1.9 billion
reuters.com
2022-04-13 02:23:00Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday.